Development of a Risk Prediction Model for Personalized Assessment of Postoperative Recurrence Risk in Colon Cancer Patients

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697747

Authors

Jing-Jing Zhang

Ya-Meng Liu

Ya-Wei Li

Zheng-Quan Han

Affiliations

Soon will be listed here.

Abstract

Background: Colon cancer, a significant contributor to cancer-related mortality worldwide, exhibits a high recurrence rate in patients following surgical intervention, particularly when the disease has progressed to intermediate or advanced stages. This study undertakes a comprehensive analysis of the risk factors influencing postoperative recurrence in patients with middle- to late-stage colon cancer and subsequently develops a columnar graphical prediction model based on these findings. This model seeks to enhance the capability of identifying the risk of postoperative recurrence in patients with intermediate and advanced colon cancer, thereby providing a scientific foundation for the development of more personalized and effective prevention and management strategies.

Methods: An analysis was conducted on a cohort of 209 patients diagnosed with colon cancer and treated at our hospital between 2020 and 2021. Clinical data were gathered to compare recurrence rates of postoperative colon cancer among patients with different influencing factors. Logistic regression analysis was utilized to determine independent factors affecting the recurrence rate of postoperative colon cancer. A nomogram risk prediction model was developed and assessed for its effectiveness.

Results: The results of the regression analysis indicated that "Tumor stage" (stage IV), "Lymph node metastasis" (presence), "the level of C-reactive protein", and "the level of carcinoembryonic antigen" were identified as independent risk factors for postoperative colon cancer recurrence in patients. Additionally, "Differentiation degree" (medium/high), "Chemotherapy (have)", and "the level of serum albumin" were found to be associated with a decreased risk of recurrence. A nomogram prediction model was created using the mentioned risk factors, showing a link between higher scores and higher postoperative colon cancer recurrence rates. The model had a C-index of 0.834 [95% confidence interval (CI): 0.776-0.892] and was internally validated for strong and consistent performance.

Conclusions: This study developed a nomogram prediction model to forecast the recurrence rate of postoperative colon cancer by identifying independent influencing factors. The model demonstrates strong discrimination and consistency, offering valuable guidance in promptly assessing the likelihood of postoperative colon cancer recurrence in patients and implementing timely and effective preventive measures.

References

Weiser M, Gonen M, Chou J, Kattan M, Schrag D . Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011; 29(36):4796-802. PMC: 3664036. DOI: 10.1200/JCO.2011.36.5080. View

Liao C, Yu Y, Lin Y, Hsu Y, Chern Y, Chiang J . Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis. World J Surg Oncol. 2021; 19(1):139. PMC: 8088626. DOI: 10.1186/s12957-021-02253-y. View

Brown J, Compton S, Meyerhardt J, Spielmann G, Yang S . The dose-response effect of aerobic exercise on inflammation in colon cancer survivors. Front Oncol. 2023; 13():1257767. PMC: 10750999. DOI: 10.3389/fonc.2023.1257767. View

Temple L . The prognosis of colon cancer is dependent on accurate staging. J Surg Oncol. 2010; 102(1):1-2. DOI: 10.1002/jso.21591. View

Fang D, Ye Y . gene rs1205 polymorphism is not associated with the risk of colorectal cancer. Biosci Rep. 2017; 37(4). PMC: 5539488. DOI: 10.1042/BSR20170872. View

Nakamura Y, Shida D, Tanabe T, Takamizawa Y, Imaizumi J, Ahiko Y . Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer. Cancer Med. 2019; 9(2):653-662. PMC: 6970051. DOI: 10.1002/cam4.2758. View

Puccini A, Berger M, Zhang W, Lenz H . What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Target Oncol. 2017; 12(3):265-275. PMC: 7489295. DOI: 10.1007/s11523-017-0494-5. View

Boden S, Zheng R, Ribbenstedt A, Landberg R, Harlid S, Vidman L . Dietary patterns, untargeted metabolite profiles and their association with colorectal cancer risk. Sci Rep. 2024; 14(1):2244. PMC: 10817924. DOI: 10.1038/s41598-023-50567-6. View

Fakih M, Sandhu J, Wang C, Kim J, Chen Y, Lai L . Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. JAMA Netw Open. 2022; 5(3):e221093. PMC: 8905389. DOI: 10.1001/jamanetworkopen.2022.1093. View

10.

Sunami E, Kusumoto T, Ota M, Sakamoto Y, Yoshida K, Tomita N . S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial. Clin Colorectal Cancer. 2020; 19(1):22-31.e6. DOI: 10.1016/j.clcc.2019.10.002. View

11.

Sugiura K, Seo Y, Tajima Y, Kikuchi H, Hirata A, Nakadai J . Prognostic Impact of Main Lymph Node Metastasis in Patients with Colon Cancer. World J Surg. 2023; 47(5):1292-1302. DOI: 10.1007/s00268-023-06918-5. View

12.

Pan H, Mi Y, Xu K, Zhang Z, Wu H, Zhang W . Association of C-reactive protein (CRP) rs1205 and rs2808630 variants and risk of cancer. J Cell Physiol. 2020; 235(11):8571-8584. DOI: 10.1002/jcp.29701. View

13.

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(1):11-9. DOI: 10.1056/NEJMoa1215340. View

14.

Dawood Z, Moazzam Z, Pawlik T . ASO Author Reflections: Assessing the Diagnostic Accuracy of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen to Detect Recurrent Colon Cancer. Ann Surg Oncol. 2022; 30(1):275-276. DOI: 10.1245/s10434-022-12678-8. View

15.

Jiang Z, Li Y, Han G, Zhang J, Li Z, Wang D . [Association of serum albumin level with clinicopathologic features and prognosis in colon cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016; 19(1):80-3. View

16.

Yang P, Xu Z, Chen T, He Z . Long noncoding RNA expression profile analysis of colorectal cancer and metastatic lymph node based on microarray data. Onco Targets Ther. 2016; 9:2465-78. PMC: 4853163. DOI: 10.2147/OTT.S102348. View

17.

Liu Q, Luo D, An H, Zhang S, Cai S, Li Q . Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer. J Cancer. 2019; 10(5):1209-1215. PMC: 6400679. DOI: 10.7150/jca.28917. View

18.

Andre T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I . Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020; 21(12):1620-1629. PMC: 7786835. DOI: 10.1016/S1470-2045(20)30527-1. View

19.

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

20.

Boden S, Myte R, Harbs J, Sundkvist A, Zingmark C, Lofgren Burstrom A . C-reactive Protein and Future Risk of Clinical and Molecular Subtypes of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020; 29(7):1482-1491. DOI: 10.1158/1055-9965.EPI-19-1339. View